The European Menopause and Andropause Society (EMAS) provides guidelines and education on menopause and andropause. These include information on the diagnosis, treatment, and management of symptoms such as hot flashes, sleep disturbances, and sexual dysfunction.
EMAS also offers educational resources for healthcare professionals, including training on menopause management and updates on the latest research findings. The society aims to improve the quality of life for individuals going through menopause and andropause and enhance the knowledge and skills of healthcare professionals caring for them.
EMAS is proud to publish position statements written by international experts on management of health conditions affecting midlife health and beyond. Recommendations are evidence-based and suitable for integration into local guidelines worldwide
Maturitas. 14 October 2023
Maturitas. 21 December 2022
Maturitas. 2 February 2022
15 July 2021
Maturitas. 2020 Sep; 139:90-97
Maturitas. January 2020; 131:91-101
Maturitas. July 2017; 101:23-30
Maturitas. 2017 Jan; 95:65-71
Maturitas 2016; 89:63-72
Maturitas. 2016; 85: 79-81
Maturitas. 2016; 84:94-9
Maturitas. 2015; 81:88-92
Maturitas. 2015; 81:410-3
Maturitas. 2014; 79:481-486
Maturitas. 2014; 79:106– 116
Maturitas. 2014; 78:131–137
Maturitas. 2014; 78:67– 69
Maturitas. 2014; 77:85–89
Maturitas. 2013; 76:200–4
2012 Jan.; 71:83–8
Women’s health is increasingly recognized as a global health priority. Managing perimenopausal and postmenopausal health is a key issue worldwide. Therefore, EMAS is making available all short fact sheets to help women, healthcare and non-healthcare professionals understand menopausal health.
Written by international experts, EMAS publishes clinical guides to provide models of care for health and allied health professionals dealing with menopause and midlife health. The guides are evidence-based and suitable for integration into local protocols worldwide.
Maturitas 2022; 163, P1-14
Maturitas 2021; 148: 55-61
Maturitas 2021; 143: 223–230
Maturitas 2020; 135: 82–88
Maturitas. 2018; 117:6–10
Maturitas. 2018; 110:118–123
Maturitas. 2018; 107:7-12
Maturitas. 2013; 75:181-90
Maturitas. 2013; 74:289-292
Maturitas. 2012; 73:171-4
Maturitas. 2012; 71:194-8
In 2023 the global female population is over 4 billion. Women form a large part of workforces worldwide, and many will be working throughout their menopausal years.
Women with severe menopause symptoms may exit employment or reduce their working hours, with a negative effect on income and security in later life. For employers, this means the loss of experienced staff with valuable skills and talent.
Thus, EMAS is leading in health and wellbeing frameworks and policies to incorporate menopausal health as part of the wider context of gender and age equality and reproductive and post-reproductive health.
Writing and publishing research papers, reviews and case reports.
Below you will find links to resources for preparing submissions.
2020, e00204. doi.org/10.1016/j.crwh.2020.e00204.
The global AWARE (Appropriate care for Women with AndRogen Excess) group is a panel of independent physicians with an expert interest in androgen excess. Their mission is to address the unmet need in androgen excess to ensure that women receive appropriate care. Since its formation in 2015, the AWARE group and its ongoing work is supported by Bayer. The group have created a number of useful resources that are available to download below. These resources aim to support healthcare professionals in the recognition, diagnosis and appropriate treatment of androgen excess. You may want to use these materials to support discussions with colleagues, for example, in a workshop setting.
Formation of the AWARE group and its ongoing work is supported and funded by Bayer AG.